Oral Nirmatrelvir–Ritonavir as Postexposure Prophylaxis for Covid-19
New England Journal of Medicine · 2024
DOI: 10.1056/nejmoa2309002 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, 2024. Verfasst von Jennifer Hammond und 12 weiteren Autor:innen. Beteiligte Einrichtung: From Global Product Development, Pfizer, Collegeville, PA (J.H.); Global Product Development, Pfizer, Lake Mary (C.Y.), and Global Product Developmen…. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19, COVID-19 Drug Treatment, Post-Exposure Prophylaxis. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Pfizer, Pfizer Inc.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From Global Product Development, Pfizer, Collegeville, PA (J.H.); Global Product Development, Pfizer, Lake Mary (C.Y.), and Global Product Development, Pfizer, Tampa (J.M.R.) - both in Florida; Global Product Developmen…
ORCID-Profile: Holly Soares
Förderung
- Pfizer
- Pfizer Inc
Zitieren
APA
Hammond, J., Yunis, C., Fountaine, R. J., Luscan, G., Burr, A. M., Zhang, W., Wisemandle, W., Soares, H., Baniecki, M. L., Hendrick, V. M., Kalfov, V., Pypstra, R., & Rusnak, J. M. (2024). Oral Nirmatrelvir–Ritonavir as Postexposure Prophylaxis for Covid-19. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2309002
Vancouver
Hammond J, Yunis C, Fountaine RJ, Luscan G, Burr AM, Zhang W, et al. Oral Nirmatrelvir–Ritonavir as Postexposure Prophylaxis for Covid-19. New England Journal of Medicine. 2024. doi:10.1056/nejmoa2309002
BibTeX
@article{Hammond2024,
author = {Hammond, Jennifer and Yunis, Carla and Fountaine, Robert J and Luscan, Gerald and Burr, Aimee M and Zhang, Wuyan and Wisemandle, Wayne and Soares, Holly and Baniecki, Mary Lynn and Hendrick, Victoria M and Kalfov, Veselin and Pypstra, Rienk and Rusnak, James M},
title = {Oral Nirmatrelvir–Ritonavir as Postexposure Prophylaxis for Covid-19},
journal = {New England Journal of Medicine},
year = {2024},
doi = {10.1056/nejmoa2309002}
}
EUVIMED